Cargando…

Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis

Accelerated-phase myelofibrosis, currently defined by circulating blasts 10% to 19%, usually confers very high risk for progression and poor outcome. The outcome of hematopoietic stem cell transplantation for accelerated-phase myelofibrosis has not been evaluated yet. We analyzed the outcome of 349...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gagelmann, Nico, Wolschke, Christine, Salit, Rachel B., Schroeder, Thomas, Ditschkowski, Markus, Panagiota, Victoria, Cassinat, Bruno, Thol, Felicitas, Badbaran, Anita, Robin, Marie, Reinhardt, Hans Christian, Ayuk, Francis, Heuser, Michael, Scott, Bart L., Kröger, Nicolaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864646/ https://www.ncbi.nlm.nih.gov/pubmed/35051996 http://dx.doi.org/10.1182/bloodadvances.2021006827

Ejemplares similares

High Molecular and Cytogenetic Risk in Myelofibrosis Does Not Benefit From Higher Intensity Conditioning Before Hematopoietic Cell Transplantation: An International Collaborative Analysis
por: Gagelmann, Nico, et al.
Publicado: (2022)

P1024: IMPACT OF TP53 IN MYELOFIBROSIS UNDERGOING STEM CELL TRANSPLANTATION
por: Gagelmann, N., et al.
Publicado: (2022)

Use of ropeginterferon in inducing graft versus myelofibrosis effect in post‐transplant myelofibrosis relapse
por: Srivastava, Barnali, et al.
Publicado: (2023)

Donor Lymphocyte Infusion and Molecular Monitoring for Relapsed Myelofibrosis After Hematopoietic Cell Transplantation
por: Gagelmann, Nico, et al.
Publicado: (2023)

TKI Maintenance After Stem-Cell Transplantation for FLT3-ITD Positive Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis
por: Gagelmann, Nico, et al.
Publicado: (2021)

Digital-droplet PCR assays for IDH, DNMT3A and driver mutations to monitor after allogeneic stem cell transplantation minimal residual disease of myelofibrosis
por: Mannina, Daniele, et al.
Publicado: (2022)

Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients
por: Gagelmann, Nico, et al.
Publicado: (2023)

Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend “when and for whom” in 2021?
por: Gagelmann, Nico, et al.
Publicado: (2021)

Treosulfan-Based Conditioning Regimen for Second Allograft in Patients with Myelofibrosis
por: Atagunduz, Isik Kaygusuz, et al.
Publicado: (2020)

Population Pharmacokinetics of Busulfan and Its Metabolite Sulfolane in Patients with Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation
por: Dadkhah, Adrin, et al.
Publicado: (2022)

Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis
por: Gagelmann, Nico, et al.
Publicado: (2021)

Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis
por: Perram, Jacinta, et al.
Publicado: (2022)

Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation
por: Massoud, Radwan, et al.
Publicado: (2021)

Impact of Anti-T-lymphocyte globulin dosing on GVHD and Immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation
por: Massoud, Radwan, et al.
Publicado: (2022)

Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis
por: Oh, Stephen T., et al.
Publicado: (2023)

Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapy
por: Berger, Susanna Carolina, et al.
Publicado: (2022)

A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis
por: Maffioli, Margherita, et al.
Publicado: (2022)

Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
por: Gupta, Vikas, et al.
Publicado: (2023)

Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study
por: Ali, Haris, et al.
Publicado: (2022)

Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials
por: Verstovsek, Srdan, et al.
Publicado: (2023)

Reply to Shao and Zhou
por: Gagelmann, Nico, et al.
Publicado: (2022)

Endothelial complications after allogeneic stem cell transplantation in patients with pretransplant resolved COVID-19
por: Niederwieser, Christian, et al.
Publicado: (2022)

Stem cell transplantation in myelofibrosis
por: Kröger, Nicolaus
Publicado: (2018)

P1398: AXICABTAGENE CILOLEUCEL VERSUS TISAGENLECLEUCEL CAR-T CELLS IN RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
por: Gagelmann, Nico, et al.
Publicado: (2023)

Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications
por: Döhner, Hartmut, et al.
Publicado: (2022)

Replacement of hematopoietic system by allogeneic stem cell transplantation in myelofibrosis patients induces rapid regression of bone marrow fibrosis
por: Kröger, Nicolaus, et al.
Publicado: (2012)

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine
por: Döhner, Hartmut, et al.
Publicado: (2022)

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
por: Robin, Marie, et al.
Publicado: (2019)

Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL
por: Wieduwilt, Matthew J., et al.
Publicado: (2021)

Digital PCR Assays for Precise Quantification of CD19-CAR-T Cells after Treatment with Axicabtagene Ciloleucel
por: Fehse, Boris, et al.
Publicado: (2020)

Open-label pilot study of romiplostim for thrombocytopenia after autologous hematopoietic cell transplantation
por: Scordo, Michael, et al.
Publicado: (2022)

Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study
por: Gagelmann, Nico, et al.
Publicado: (2022)

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial
por: de Botton, Stéphane, et al.
Publicado: (2023)

Accurate In-Vivo Quantification of CD19 CAR-T Cells after Treatment with Axicabtagene Ciloleucel (Axi-Cel) and Tisagenlecleucel (Tisa-Cel) Using Digital PCR
por: Badbaran, Anita, et al.
Publicado: (2020)

Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level
por: Modemann, Franziska, et al.
Publicado: (2020)

Correction: Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level
por: Modemann, Franziska, et al.
Publicado: (2021)

CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany
por: Bader, Peter, et al.
Publicado: (2023)

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3(mut+) AML ineligible for intensive chemotherapy
por: Wang, Eunice S., et al.
Publicado: (2022)

Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study
por: Ayuk, Francis, et al.
Publicado: (2023)

Treatment for Relapsed/Refractory Acute Myeloid Leukemia
por: Thol, Felicitas, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5rd8p1c4di2hsd0haql6pk4rh6